Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • GnRH Antagonists Modified with 3-(2-Methoxy-5-pyridyl)-alani

    2026-05-01

    Evaluating Stereochemical Modifications of GnRH Antagonists: Implications for Peptide Therapeutic Development

    Study Background and Research Question

    Gonadotropin-releasing hormone (GnRH) is a decapeptide hormone central to regulating reproductive function via pituitary gonadotropin release. Peptide-based GnRH antagonists have emerged as important therapeutic candidates for conditions such as hormone-dependent cancers and endometriosis, offering advantages over agonists by producing rapid suppression without an initial hormone surge (source: paper). A persistent challenge, however, is the development of antagonists that combine high potency, metabolic stability, and long-lasting in vivo effects. The reference study addresses whether introducing a specific unnatural amino acid, 3-(2-methoxy-5-pyridyl)-alanine (2-OMe-5Pal), at position 3 in degarelix can optimize these properties.

    Key Innovation from the Reference Study

    The primary innovation lies in the stereoselective modification of degarelix—a clinically advanced GnRH antagonist—by replacing the conventional residue at position 3 with either D- or L-configured 2-OMe-5Pal. The two resulting diastereomers were separated and individually characterized to assess the influence of stereochemistry on receptor antagonism and duration of action. By leveraging unnatural amino acids, the authors probe the structure-activity relationship at a key pharmacophore position that is known to affect both potency and metabolic stability (source: paper).

    Methods and Experimental Design Insights

    The research team synthesized both D- and L-2-OMe-5Pal analogs of degarelix using solid-phase peptide synthesis (SPPS) protocols, followed by purification with reverse-phase high-performance liquid chromatography (RP-HPLC). The absolute configuration at position 3 was verified through enzymatic digestion using proteinase K, exploiting the enzyme's stereospecificity. Analytical confirmation was performed by mass spectrometry (ESI-MS, MALDI-MS) and NMR. In vitro assays measured antagonism of the human GnRH receptor, reporting IC50 values for each analog. For in vivo assessment, the compounds were administered subcutaneously to castrated male rats, a standard model for evaluating the suppression of gonadotropin-driven physiology. The duration of action was compared to unmodified degarelix.

    Protocol Parameters

    • assay | solid-phase peptide synthesis (SPPS) | Fmoc chemistry, RP-HPLC purification | applicable for synthesizing peptide analogs with unnatural residues | Ensures sequence fidelity and high yield for SAR studies | source: paper
    • in vitro GnRH receptor antagonism | IC50 (D-2-OMe-5Pal: 5.22 nM; L-2-OMe-5Pal: 36.95 nM) | human recombinant receptor, cell-based | Quantifies potency of modified antagonists | Direct comparison of diastereomeric effects | source: paper
    • in vivo duration of action | short-acting relative to parent degarelix | castrated male rat | Assesses pharmacodynamic persistence | Reveals the impact of modification on half-life | source: paper
    • workflow recommendation | use high-purity reagents for peptide synthesis and receptor assays | broad applicability | Minimizes batch variability and enhances reproducibility in SAR studies | workflow_recommendation

    Core Findings and Why They Matter

    The study demonstrates a pronounced stereochemical effect: the D-configured analog (D-2-OMe-5Pal at position 3) retains high in vitro potency (IC50 = 5.22 nM), while the L-isomer (L-2-OMe-5Pal) shows markedly reduced activity (IC50 = 36.95 nM) (source: paper). Despite this, both analogs exhibited only short-acting profiles in vivo, contrasting with the long-acting nature of unmodified degarelix. This indicates that while specific unnatural amino acid substitutions can preserve or even enhance in vitro receptor affinity, they may also compromise systemic stability or in vivo pharmacokinetics—critical considerations for therapeutic development. The results highlight the need for careful balance between optimizing receptor binding and ensuring metabolic resilience.

    Comparison with Existing Internal Articles

    Several internal resources expand on the themes of receptor modulation and the methodological approaches used in this study. For example, the article "GnRH Antagonists with 3-(2-Methoxy-5-pyridyl)-alanine: Synthesis and Bioactivity Insights" (budipinesource.com) offers further discussion on how unnatural amino acid substitutions affect bioactivity profiles and details the stereochemical challenges in peptide drug design. Similarly, articles focusing on synthetic antioxidants such as butylated hydroxyanisole (BHA) highlight the broader context of oxidative stress research, where precise modulation of signaling pathways—including apoptosis and inflammation—is crucial (pelubiprofenshop.com). While these domains differ, the common emphasis on molecular precision and assay reliability underscores the interconnectedness of peptide chemistry and redox biology in translational research.

    Limitations and Transferability

    A notable limitation of the reference study is that the in vivo models employed (castrated male rats) may not fully predict pharmacokinetic performance in humans. Additionally, while the D-2-OMe-5Pal analog maintained in vitro potency, the short-acting profile suggests that other factors—such as peptide degradation or altered distribution—may counteract receptor affinity gains. As with many peptide therapeutics, translation from bench to clinic requires iterative optimization, including further modification to enhance metabolic stability or formulation strategies to prolong action (source: paper). Transferability to other peptide or small molecule systems should be approached with caution, as stereochemical effects can vary depending on sequence context and target.

    Research Support Resources

    For researchers seeking to replicate or extend these workflows—particularly those involving receptor modulation, apoptosis signaling pathway analysis, and oxidative stress research—robust antioxidant controls are essential. Butylhydroxyanisole (BHA) (SKU C6525) offers a high-purity, research-grade option for modulating reactive oxygen species (ROS) in cellular assays. As a synthetic antioxidant, BHA is especially suited for studies requiring consistent free radical scavenging and reproducible redox environment control (workflow_recommendation). For further methodological context, readers may refer to the internal article "Butylated Hydroxyanisole: Synthetic Antioxidant for Oxida..." (pelubiprofenshop.com), which details best practices in oxidative stress and cellular protection workflows.